{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:49:47Z","timestamp":1792079387504,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["AcSe program"],"award-info":[{"award-number":["AcSe program"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41591-023-02382-9","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T12:02:12Z","timestamp":1685361732000},"page":"1358-1363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-232X","authenticated-orcid":false,"given":"Manuel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Penard-Lacronique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Darin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim-Maria","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Duchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Lamazi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Desmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Pontoizeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schenkein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Ottolenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"De Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"2382_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1192632","volume":"330","author":"M Kranendijk","year":"2010","unstructured":"Kranendijk, M. et al. IDH2 mutations in patients with d-2-hydroxyglutaric aciduria. Science 330, 336 (2010).","journal-title":"Science"},{"key":"2382_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10545-012-9462-5","volume":"35","author":"M Kranendijk","year":"2012","unstructured":"Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S. & Jakobs, C. Progress in understanding 2-hydroxyglutaric acidurias. J. Inherit. Metab. Dis. 35, 571\u2013587 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"2382_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF02312516","volume":"3","author":"RA Chalmers","year":"1980","unstructured":"Chalmers, R. A. et al. D-2-hydroxyglutaric aciduria: case report and biochemical studies. J. Inherit. Metab. Dis. 3, 11\u201315 (1980).","journal-title":"J. Inherit. Metab. Dis."},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"eaaw4543","DOI":"10.1126\/sciadv.aaw4543","volume":"5","author":"S Tommasini-Ghelfi","year":"2019","unstructured":"Tommasini-Ghelfi, S. et al. Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease. Sci. Adv. 5, eaaw4543 (2019).","journal-title":"Sci. Adv."},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225\u2013234 (2010).","journal-title":"Cancer Cell"},{"key":"2382_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010).","journal-title":"Cancer Cell"},{"key":"2382_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","volume":"12","author":"R Chowdhury","year":"2011","unstructured":"Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463\u2013469 (2011).","journal-title":"EMBO Rep."},{"key":"2382_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400\u2013404 (2018).","journal-title":"Nature"},{"key":"2382_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 1015\u20131023 (2018).","journal-title":"Nat. Med."},{"key":"2382_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722\u2013731 (2017).","journal-title":"Blood"},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","volume":"7","author":"K Yen","year":"2017","unstructured":"Yen, K. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7, 478\u2013493 (2017).","journal-title":"Cancer Discov."},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10545-016-9960-y","volume":"39","author":"F Wang","year":"2016","unstructured":"Wang, F. et al. A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model. J. Inherit. Metab. Dis. 39, 807\u2013820 (2016).","journal-title":"J. Inherit. Metab. Dis."},{"key":"2382_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1101\/gad.231233.113","volume":"28","author":"EA Akbay","year":"2014","unstructured":"Akbay, E. A. et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 28, 479\u2013490 (2014).","journal-title":"Genes Dev."},{"key":"2382_CR14","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/JCO.21.01152","volume":"39","author":"F Bautista","year":"2021","unstructured":"Bautista, F. et al. Phase I or II study of ribociclib in combination with topotecan-temozolomide or everolimus in children with advanced malignancies: arms A and B of the AcS\u00e9-ESMART trial. J. Clin. Oncol. 39, 3546\u20133560 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2382_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22450-3","volume":"12","author":"T Nishina","year":"2021","unstructured":"Nishina, T. et al. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat. Commun. 12, 2281 (2021).","journal-title":"Nat. Commun."},{"key":"2382_CR16","doi-asserted-by":"publisher","first-page":"109634","DOI":"10.1016\/j.celrep.2021.109634","volume":"36","author":"P Maity","year":"2021","unstructured":"Maity, P. et al. Persistent JunB activation in fibroblasts disrupts stem cell niche interactions enforcing skin aging. Cell Rep. 36, 109634 (2021).","journal-title":"Cell Rep."},{"key":"2382_CR17","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.1073\/pnas.1601650113","volume":"113","author":"A Karlstaedt","year":"2016","unstructured":"Karlstaedt, A. et al. Oncometabolite d-2-hydroxyglutarate impairs \u03b1-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc. Natl Acad. Sci. USA 113, 10436\u201310441 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2018.09.074","volume":"25","author":"MG Badur","year":"2018","unstructured":"Badur, M. G. et al. Oncogenic R132 IDH1 mutations limit NADPH for de novo lipogenesis through (D)2-hydroxyglutarate production in fibrosarcoma cells. Cell Rep. 25, 1018\u20131026 (2018).","journal-title":"Cell Rep."},{"key":"2382_CR19","doi-asserted-by":"publisher","first-page":"e123231","DOI":"10.1172\/jci.insight.123231","volume":"4","author":"M Ruiz","year":"2019","unstructured":"Ruiz, M. et al. Lipidomics unveils lipid dyshomeostasis and low circulating plasmalogens as biomarkers in a monogenic mitochondrial disorder. JCI Insight 4, e123231 (2019).","journal-title":"JCI Insight"},{"key":"2382_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fneur.2020.00437","volume":"11","author":"AV Alessenko","year":"2020","unstructured":"Alessenko, A. V. & Albi, E. Exploring sphingolipid implications in neurodegeneration. Front. Neurol. 11, 437 (2020).","journal-title":"Front. Neurol."},{"key":"2382_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2021.08.010","volume":"157","author":"RJ Morscher","year":"2021","unstructured":"Morscher, R. J. et al. First-in-child phase I\/II study of the dual mTORC1\/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcS\u00e9-ESMART trial. Eur. J. Cancer 157, 268\u2013277 (2021).","journal-title":"Eur. J. Cancer"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","volume":"150","author":"C Pasqualini","year":"2021","unstructured":"Pasqualini, C. et al. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed\/refractory solid tumours: arm G of AcS\u00e9-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. Eur. J. Cancer 150, 53\u201362 (2021).","journal-title":"Eur. J. Cancer"},{"key":"2382_CR23","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.ejca.2013.02.028","volume":"49","author":"X Paoletti","year":"2013","unstructured":"Paoletti, X. et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults\u2019 trials. Eur. J. Cancer 49, 2392\u20132402 (2013).","journal-title":"Eur. J. Cancer"},{"key":"2382_CR24","doi-asserted-by":"crossref","unstructured":"Sparrow, S. S. in Encyclopedia of Clinical Neuropsychology (eds Kreutzer, J. S. et al.) 2618\u20132621 (Springer, 2011).","DOI":"10.1007\/978-0-387-79948-3_1602"},{"key":"2382_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jchromb.2016.04.030","volume":"1022","author":"V Poinsignon","year":"2016","unstructured":"Poinsignon, V. et al. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1022, 290\u2013297 (2016).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"2382_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","volume":"226","author":"J Folch","year":"1957","unstructured":"Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497\u2013509 (1957).","journal-title":"J. Biol. Chem."},{"key":"2382_CR27","doi-asserted-by":"publisher","first-page":"103285","DOI":"10.1016\/j.dsr.2020.103285","volume":"161","author":"B Shillito","year":"2020","unstructured":"Shillito, B. et al. Lipidome variations of deep-sea vent shrimps according to acclimation pressure: a homeoviscous response? Deep Sea Res. 1 Oceanogr. Res. Pap. 161, 103285 (2020).","journal-title":"Deep Sea Res. 1 Oceanogr. Res. Pap."},{"key":"2382_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jpba.2016.02.007","volume":"123","author":"J Escobar","year":"2016","unstructured":"Escobar, J. et al. Development of a reliable method based on ultra-performance liquid chromatography coupled to tandem mass spectrometry to measure thiol-associated oxidative stress in whole blood samples. J. Pharm. Biomed. Anal. 123, 104\u2013112 (2016).","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02382-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T07:42:22Z","timestamp":1687419742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02382-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02382-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S. is a current board member at Agios Pharmaceuticals and a current shareholder of Agios Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}